melatonin has been researched along with Squamous Cell Carcinoma of Head and Neck in 16 studies
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has a powerful antioxidant and oncostatic effects that are expected to improve tumor hypoxia and clinical response." | 2.94 | Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial. ( Abdullah, M; Haryana, SM; Jusman, SW; Kartini, D; Maruli, H; Panigoro, SS; Purwanto, DJ; Rustamadji, P; Setiabudy, R; Siregar, BH; Sungkar, S; Suroyo, I; Sutandyo, N; Taher, A, 2020) |
| "Oral squamous cell carcinomas are one of the most common cancers worldwide with aggressive behavior and poor prognosis." | 1.91 | Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS. ( Choi, WS; Li, X; Su, Y; Tao, Z; Wang, C; Wang, L; Zhu, W, 2023) |
| "Melatonin has been shown to have oncostatic effects in different types of cancers." | 1.91 | Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress. ( Acuña-Castroviejo, D; Carriel, V; Escames, G; Fernández-Gil, BI; Fernández-Martínez, J; Florido, J; García-Tárraga, P; Garcia-Verdugo, JM; González-García, P; Guerra-Librero, A; López-Rodríguez, A; Martinez-Ruiz, L; Oppel, F; Rodriguez-Santana, C; Rusanova, I; Sánchez-Porras, D; Sudhoff, H; Ten-Steve, A, 2023) |
| "Melatonin receptors can inhibit breast and prostate cancers; however, little is known regarding their effects on oral squamous cell carcinoma." | 1.72 | Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients. ( Hwang, DS; Jang, MA; Kim, GC; Kim, UK; Park, HK; Ryu, MH, 2022) |
| "The prevalence of head and neck squamous cell carcinoma (HNSCC) has continued to rise for decades." | 1.72 | Melatonin and verteporfin synergistically suppress the growth and stemness of head and neck squamous cell carcinoma through the regulation of mitochondrial dynamics. ( Ahn, JS; Kang, MJ; Kim, HS; Kim, YH; Lee, D; Oh, JM; Oh, SJ; Seo, Y; Shin, YY; Song, MH; Sung, ES, 2022) |
| "In addition, MTHFD1L promoted HNSCC progression in vitro and in vivo and reversed the oncostatic effects of exogenous melatonin." | 1.62 | Melatonin modulates metabolic remodeling in HNSCC by suppressing MTHFD1L-formate axis. ( Cui, L; Hu, S; Jin, Z; Wang, H; Yang, SF; Zhao, X, 2021) |
| "Melatonin treatment enhanced arecoline-induced ROS production, cytotoxicity, G2/M phase arrest, and cell apoptosis in OSCC cells." | 1.62 | Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma. ( Chiu, KC; Hsia, SM; Lan, WC; Shieh, TM; Shih, YH; Tsai, BH; Wang, TH; Wu, LJ, 2021) |
| "Head and neck squamous cell carcinoma (HNSCC) cells with or without melatonin treatment were used as a research platform." | 1.62 | FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis. ( Jensen, C; Lang, L; Loveless, R; Prieto-Dominguez, N; Shay, C; Teng, Y; Xiong, Y, 2021) |
| "Head and neck squamous cell carcinoma (HNSCC) clearly involves activation of the Akt mammalian target of rapamycin (mTOR) signalling pathway." | 1.48 | Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. ( Acuña-Castroviejo, D; Carriel, V; Diaz-Casado, ME; Escames, G; Fernandez-Gil, BI; Florido, J; García-López, S; Guerra-Librero, A; López, LC; Martinez-Ruiz, L; Mendivil-Perez, M; Nieto, A; Ortega-Arellano, H; Reiter, RJ; Rusanova, I; Shen, YQ; Soto-Mercado, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 13 (81.25) | 2.80 |
| Authors | Studies |
|---|---|
| Park, HK | 1 |
| Ryu, MH | 1 |
| Hwang, DS | 1 |
| Kim, GC | 1 |
| Jang, MA | 1 |
| Kim, UK | 1 |
| Cui, L | 1 |
| Zhao, X | 1 |
| Jin, Z | 1 |
| Wang, H | 2 |
| Yang, SF | 1 |
| Hu, S | 1 |
| Shigeishi, H | 1 |
| Yokoyama, S | 1 |
| Murodumi, H | 1 |
| Sakuma, M | 1 |
| Fukada, S | 1 |
| Okuda, S | 1 |
| Yamakado, N | 1 |
| Ono, S | 1 |
| Takechi, M | 1 |
| Ohta, K | 1 |
| Shin, YY | 1 |
| Seo, Y | 1 |
| Oh, SJ | 1 |
| Ahn, JS | 1 |
| Song, MH | 1 |
| Kang, MJ | 1 |
| Oh, JM | 1 |
| Lee, D | 1 |
| Kim, YH | 1 |
| Sung, ES | 1 |
| Kim, HS | 1 |
| Luo, X | 1 |
| Chen, Y | 1 |
| Tang, H | 1 |
| Jiang, E | 1 |
| Shao, Z | 1 |
| Liu, K | 1 |
| Zhou, X | 1 |
| Shang, Z | 1 |
| Wang, L | 2 |
| Wang, C | 2 |
| Tao, Z | 2 |
| Zhu, W | 2 |
| Su, Y | 2 |
| Choi, WS | 2 |
| Li, X | 1 |
| Martinez-Ruiz, L | 4 |
| Florido, J | 4 |
| Rodriguez-Santana, C | 3 |
| López-Rodríguez, A | 2 |
| Guerra-Librero, A | 3 |
| Fernández-Gil, BI | 3 |
| García-Tárraga, P | 1 |
| Garcia-Verdugo, JM | 1 |
| Oppel, F | 1 |
| Sudhoff, H | 1 |
| Sánchez-Porras, D | 1 |
| Ten-Steve, A | 1 |
| Fernández-Martínez, J | 2 |
| González-García, P | 1 |
| Rusanova, I | 2 |
| Acuña-Castroviejo, D | 4 |
| Carriel, V | 2 |
| Escames, G | 4 |
| Cela, O | 1 |
| Capitanio, N | 1 |
| Ramírez-Casas, Y | 1 |
| Kartini, D | 1 |
| Taher, A | 1 |
| Panigoro, SS | 1 |
| Setiabudy, R | 1 |
| Jusman, SW | 1 |
| Haryana, SM | 1 |
| Abdullah, M | 1 |
| Rustamadji, P | 1 |
| Purwanto, DJ | 1 |
| Sutandyo, N | 1 |
| Suroyo, I | 1 |
| Siregar, BH | 1 |
| Maruli, H | 1 |
| Sungkar, S | 1 |
| Shih, YH | 1 |
| Chiu, KC | 1 |
| Wang, TH | 1 |
| Lan, WC | 1 |
| Tsai, BH | 1 |
| Wu, LJ | 1 |
| Hsia, SM | 1 |
| Shieh, TM | 1 |
| Madapusi Balaji, T | 1 |
| Varadarajan, S | 1 |
| Jagannathan, R | 1 |
| Raj, AT | 1 |
| Sridhar, LP | 1 |
| Patil, S | 1 |
| Lang, L | 1 |
| Xiong, Y | 1 |
| Prieto-Dominguez, N | 1 |
| Loveless, R | 1 |
| Jensen, C | 1 |
| Shay, C | 1 |
| Teng, Y | 1 |
| Fan, T | 1 |
| Pi, H | 1 |
| Li, M | 1 |
| Ren, Z | 1 |
| He, Z | 1 |
| Zhu, F | 1 |
| Tian, L | 1 |
| Tu, M | 1 |
| Xie, J | 1 |
| Liu, M | 1 |
| Li, Y | 1 |
| Tan, M | 1 |
| Li, G | 1 |
| Qing, W | 1 |
| Reiter, RJ | 2 |
| Yu, Z | 1 |
| Wu, H | 1 |
| Zhou, Z | 1 |
| Shen, YQ | 2 |
| García-López, S | 2 |
| Mendivil-Perez, M | 1 |
| Soto-Mercado, V | 1 |
| Ortega-Arellano, H | 1 |
| Diaz-Casado, ME | 1 |
| Nieto, A | 1 |
| López, LC | 2 |
| Adan, C | 1 |
| Quiñones-Hinojosa, A | 1 |
| Abdel Moneim, AE | 1 |
| Rodríguez Ferrer, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC)[NCT04137627] | Phase 3 | 50 participants (Actual) | Interventional | 2017-07-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expression of CD133 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 1.13 | 1.42 | 0.43 |
| Placebo | 1.07 | 1.88 | 0.55 |
Expression of CD44 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 0.0349 | 0.0115 | -0.0114 |
| Placebo | 0.0095 | 0.0187 | 0.0082 |
Expression of HIF-1⍺ is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Median) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 0.018 | 0.012 | -0.008 |
| Placebo | 0.0048 | 0.0087 | 0.0027 |
Expression of miR-210 is measured at the initial period of the study (baseline) and after 3 neoadjuvant chemotherapy cycles are completed using qRT-PCR Absolute Quantification. Change was calculated from two time points as the value at the later time point minus the value at the earlier time point. (NCT04137627)
Timeframe: 1 Year
| Intervention | Picogram/microliter (Mean) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | Change (Posttreatment - Pretreatment) | |
| Melatonin | 162.8 | 53.8 | -109.09 |
| Placebo | 175.2 | 53.5 | -103.71 |
1 trial available for melatonin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Effect of melatonin supplementation in combination with neoadjuvant chemotherapy to miR-210 and CD44 expression and clinical response improvement in locally advanced oral squamous cell carcinoma: a randomized controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; C | 2020 |
15 other studies available for melatonin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Effects of melatonin receptor expression on prognosis and survival in oral squamous cell carcinoma patients.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastas | 2022 |
Melatonin modulates metabolic remodeling in HNSCC by suppressing MTHFD1L-formate axis.
Topics: Aminohydrolases; Cell Line, Tumor; Formate-Tetrahydrofolate Ligase; Formates; Gene Expression Regula | 2021 |
Melatonin enhances cisplatin-induced cell death through inhibition of DERL1 in mesenchymal-like CD44
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Gene Expressi | 2022 |
Melatonin and verteporfin synergistically suppress the growth and stemness of head and neck squamous cell carcinoma through the regulation of mitochondrial dynamics.
Topics: Cell Line, Tumor; Head and Neck Neoplasms; Humans; Melatonin; Mitochondrial Dynamics; Neoplastic Ste | 2022 |
Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.
Topics: Animals; B7-H1 Antigen; Epithelial-Mesenchymal Transition; Head and Neck Neoplasms; MAP Kinase Signa | 2022 |
Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF/NLRP3/IL-1β circuit: A crosstalk interrupted by melatonin.
Topics: Animals; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Intramolecular Oxidoreductases; | 2023 |
Melatonin and erastin emerge synergistic anti-tumor effects on oral squamous cell carcinoma by inducing apoptosis, ferroptosis, and inhibiting autophagy through promoting ROS.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Disease Models, Animal; Ferroptosis; Head a | 2023 |
Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Head and Neck Neoplasms; Heterografts; Humans | 2023 |
The Relationship between Clock Genes, Sirtuin 1, and Mitochondrial Activity in Head and Neck Squamous Cell Cancer: Effects of Melatonin Treatment.
Topics: Circadian Rhythm; Head and Neck Neoplasms; Humans; Melatonin; Neoplasms, Squamous Cell; Sirtuin 1; S | 2023 |
Effects of melatonin to arecoline-induced reactive oxygen species production and DNA damage in oral squamous cell carcinoma.
Topics: Areca; Arecoline; Carcinoma, Squamous Cell; DNA Damage; Humans; Melatonin; Mouth Neoplasms; Reactive | 2021 |
Hypothesizing the potential role of melatonin in inhibiting epithelial to mesenchymal transition in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Melatonin; Mo | 2020 |
FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Topics: Animals; Fibroblast Growth Factors; Humans; Melatonin; Mice; Neoplasm Metastasis; Receptor, Fibrobla | 2021 |
Inhibiting MT2-TFE3-dependent autophagy enhances melatonin-induced apoptosis in tongue squamous cell carcinoma.
Topics: Adult; Aged; Animals; Antioxidants; Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Tran | 2018 |
Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell L | 2018 |
Melatonin Enhances Cisplatin and Radiation Cytotoxicity in Head and Neck Squamous Cell Carcinoma by Stimulating Mitochondrial ROS Generation, Apoptosis, and Autophagy.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Autophagy; Cisplatin; Humans; Melatonin; Mitochondri | 2019 |